BioAge valued at $758 mln in debut as investors bet on weight-loss drug …
WEB1 day ago · Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
WEB19 hours ago · BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on...
A weight loss drug developer's stock soars after a $198 million …
WEB1 day ago · Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday.
BioAge prices $198M IPO, validating pivot to obesity drug research
WEB2 days ago · BioAge Labs has raised $198 million in an initial public offering, the company announced Wednesday, capitalizing on intense investor interest in drugs that can promote weight loss.
Weight-loss drug developer BioAge Labs aims to raise $198M …
WEB1 day ago · Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of...
Obesity drug developer BioAge seeks up to $587 mln valuation in …
WEBSep 18, 2024 · Bioage's experimental drug, azelaprag, is being developed to treat obesity, in combination with GLP-1 agonists such as Eli Lilly's (LLY.N) Zepbound and Novo Nordisk's (NOVOb.CO) Wegovy. Some...
BioAge Announces First Patient Dosed in the STRIDES Phase 2 …
WEBJul 29, 2024 · Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation.
BioAge stock rallies 29% following upsized $198M IPO
WEB1 day ago · BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.
BioAge Labs IPO: stock price today in high-profile Nasdaq debut
WEB1 day ago · California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class …
WEBOct 26, 2023 · Preclinical data show that drug co-administration significantly increases total weight loss and improves body composition vs. tirzepatide alone. Phase 2 trial is planned to start in mid-2024.
Skip to content